Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Returning to Boston for its 13 th edition, the IMPACCT Real-World Evidence Summit remains the go-to meeting for RWE experts ...

The global brain cancer treatment market is rapidly evolving, driven by the increasing incidence of brain cancer and advancements in medical technology focusing on personalized medicine. With ...

Multiple Sclerosis, the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. The r ...

Dr. Green's appointment is anticipated to bring valuable expertise in clinical oncology, pipeline development, and business ...

In a Phase I/II clinical trial, TKI-pretreated NSCLC patients given zidesamtinib had an overall response rate of 44 percent.

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.